Abstract
GWASs have identified numerous genetic variants associated with a wide variety of diseases, yet despite the wide availability of genetic testing the insights that would enhance the interpretability of these results are not widely available to members of the public. As a proof of concept and demonstration of technological feasibility, we developed PAGEANT (Personal Access to Genome & Analysis of Natural Traits), usable through Graphical User Interface or command line-based version, aiming to serve as a protocol and prototype that guides the overarching design of genetic reporting tools. PAGEANT is structured across five core modules, summarized by five Qs: (1) Quality assurance of the genetic data; (2) Qualitative assessment of genetic characteristics; (3) Quantitative assessment of health risk susceptibility based on polygenic risk scores and population reference; (4) Query of third-party variant databases (e.g., ClinVAR and PharmGKB); and (5) Quick Response code of genetic variants of interest. Literature review was conducted to compare PAGEANT with academic and industry tools. For 2,504 genomes made publicly available through the 1,000 Genomes Project, we derived their genomic characteristics for a suite of qualitative and quantitative traits. One exemplary trait is susceptibility to COVID-19, based on the most up-to-date scientific findings reported.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Huang was supported by Grant 2020YFC2002900 from the National Key Research and Development Program of China, and Peking University Research Initiation Fund (BMU2018YJ009).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The 1000 Genomes Project (G1K) genetic data [20] are the foundation for most GWAS and PRS studies, and this is used as the default reference panel (https://www.internationalgenome.org/data/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
PAGEANT code is available at https://github.com/jielab/pageant
